Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study
Background Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become the standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains inevitable. Current post-progression salvage regimens offer only modest clinical benefits, leaving...